BioGenex, a pioneer in automated staining solution provider for cancer diagnostics announces the launch of three new primary immunohistochemistry (IHC) antibodies for cancer diagnosis. The new launch includes:
CD8A: Studies have confirmed that CD8 expression is a recurrent albeit rare phenomenon in patients with CLL and suggests CD8 expression has an adverse prognostic impact. Read more
CD56: CD56 is a phenotypical marker for natural killer cells and many other immune cells, including alpha-beta T cells, gamma delta T cells, dendritic cells and monocytes and can be used to distinguish many tumors such as myeloma, Wilm’s Tumor, neuroblastoma, Ewing’s Sarcoma and many others. Read more
CD163: CD163 can interact and bind with gram-positive and gram-negative bacteria, functioning like a macrophage receptor. Read more
ha-beta T cells, gamma delta T cells, dendritic cells and monocytes and can be used to
BioGenex offers over 400 antibodies for various panels in ready-to-use and concentrated format. Our antibodies are compatible with fully automated staining systems and detection systems for clean and intense staining.
Subscribe to our newsletter
Don't miss out on the latest news, exclusive updates, and special offers.
Do you have questions? Contact Us